A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: an NRG Oncology/Gynecologic Oncology Group Study

OBJECTIVE: Preclinical data suggest elesclomol increases oxidative stress and enhances sensitivity to cytotoxic agents. The objective of this prospective multicenter phase 2 trial was to estimate the activity of IV elesclomol plus weekly paclitaxel in patients with platinum-resistant recurrent ovari...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Gynecol Oncol
मुख्य लेखकों: Monk, Bradley J., Kauderer, James T., Moxley, Katherine M., Bonebrake, Albert J., Dewdney, Summer B., Alvarez Secord, Angeles, Ueland, Frederick R., Johnston, Carolyn M., Aghajanian, Carol
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2018
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6392076/
https://ncbi.nlm.nih.gov/pubmed/30309721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.10.001
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन